Navigation Links
RSCI Announces Two Additions to Its Science Advisory Board, Calling for More Stem Cell Research on Diabetes
Date:10/20/2008

WASHINGTON, Oct. 20 /PRNewswire/ -- The Repair Stem Cell Institute (RSCI) today announced two additions to its world-leading Science Advisory Board (SAB), extending its stem cell research proficiency in the process. Don Margolis, RSCI chairman, noted that "Our first five appointees had two things in common: pioneering stem cell research and successfully helping patients with a variety of illnesses considered incurable. Today we add two Massachusetts researchers, David Matzilevich, M.D., Ph.D. and Mariano Ubeda, M.D., Ph.D. thus stretching our expertise to fields not being covered by others. They fit well with our innovative five."

According to Margolis, the two new additions cover still more ground. "Dr. Matzilevich's focus is on adult stem cell and cord blood uses as well as molecular-based approaches to Schizophrenia and Bipolar Disorder, and he is contributing greatly to these fields. Dr. Ubeda has made significant scientific contributions to the field of chronic degenerative diseases, and is working on advanced stem cell therapies to try to combat the greatest pandemic in world medical history--Diabetes--a disease for which current stem cell research doesn't begin to match the need. We at RSCI are committed to improving the lives of diabetic patients.

"Our SAB Chairman, Kit Arom, M.D., Ph.D. of Minneapolis and Bangkok, is the first doctor in the world to personally inject stem cells into the heart muscles of over 100 late-stage heart patients, accepting patients with no other options by standard cardiology and improving their lives at a 70% success rate. Now he wants to get involved in the fight against the diabetes pandemic.

"Deputy Chairman Roberto Fernandez Vina, M.D. of Argentina is a world-pioneer, having completed successful clinical trials on heart patients in South America before the first such trial even started in the USA. He is also the author of the first stem cell clinical trial for type 2 Diabetes.

"Zannos Grekos, M.D. is the only cardiologist in the world to offer critically-ill American heart patients a full program of stem cell therapy including about two years of pre and post treatment care. Now he wants to help in the battle against diabetes, and we are delighted to have his support."

Carlos Lima, M.D. adds still another specialty to RSCI's SAB. He is the world's pioneer stem cell physician for spinal cord injured paraplegics. "Dr. Lima has some of them actually walking with braces and walkers, after years of special rehabilitation," says Margolis, "It's not an easy battle, but Dr. Lima is leading the way.

"Rounding out our panel is Shimon Slavin, M.D. of Israel. He was the first in the world to go beyond bone marrow transplants and help cancer patients with cellular therapy. He was also first to cure a bubble baby with cellular therapy--a task other stem cell researchers are still struggling with."

ABOUT RSCI:

The Repair Stem Cell Institute LLC (RSCI) is a global public service firm dedicated to educating the public about repair stem cells/adult stem cell research and treatments worldwide. RSCI was founded in April 2008 with offices in Washington, D.C., Dallas, Texas and Bangkok, Thailand.


'/>"/>
SOURCE The Repair Stem Cell Institute LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ADVENTRX Announces Restructuring and Cost Reduction Initiatives
2. Resverlogix Announces Closing of Debt Redemption
3. Pittsburgh Technology Council Announces Technology 50
4. China Bio Energy Holdings Group Announces Financing and Exercise of Warrants
5. Pioneer(R) Surgical Technology Announces First Human Implants of New nanOss(TM)-Cervical Fusion Device
6. CryoLife Announces Release Date and Teleconference Call Details for Third Quarter 2008 Financial Results
7. Exiqon A/S Announces U.S. Subsidiary Name Change From Oncotech, Inc. to Exiqon Diagnostics, Inc.
8. Vasogen Announces Third Quarter 2008 Results
9. Volcano Corporation Announces Launch of PrimeWire(TM) Pressure Guidewire and s5-FFR Option for Existing Fleet of s5 IVUS Consoles
10. SourceSolution Announces the Launch of Its Initiative to Simplify Outsourcing Decisions for Biotechnology and Pharmaceutical Companies
11. Ground Zero Pharmaceuticals Announces Expansion of Regulatory and Product Development Consulting Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/11/2017)... Washington, USA (PRWEB) , ... January 11, 2017 ... ... SPIE, the international society for optics and photonics , are commending the U.S. ... photonics, following the signing Friday by the President of the American Innovation and ...
(Date:1/11/2017)... Francisco, CA (PRWEB) , ... January 11, 2017 ... ... series of in-kind scientific grants to ground-breaking microbiome studies. Its most recent microbiome ... School of Medicine, who will study the effect of long-term use of oral ...
(Date:1/11/2017)... ... January 11, 2017 , ... Back pain relief technology ... Shots and No Surgery for positive back pain relief for WAR members. , This ... worldwide and could be life changing for millions suffering from chronic back pain. , ...
(Date:1/11/2017)...  GenVec, Inc. (NASDAQ: GNVC ), ... its chief scientific officer, Douglas E. Brough ... for translational development of innovative gene and cell ... Phacilitate Cell & Gene Therapy World 2017 Conference ... Brough,s presentation will highlight the utility of the ...
Breaking Biology Technology:
(Date:12/15/2016)... 2016 "Increase in mobile transactions is driving ... biometrics market is expected to grow from USD 4.03 ... at a CAGR of 29.3% between 2016 and 2022. ... growing demand for smart devices, government initiatives, and increasing ... component is expected to grow at a high rate ...
(Date:12/7/2016)... 2016 According to a new market research report "Emotion ... Expression, Voice Recognition), Service, Application Area, End User, And Region - Global Forecast ... USD 6.72 Billion in 2016 to USD 36.07 Billion by 2021, at a ... Reading ... MarketsandMarkets Logo ...
(Date:12/6/2016)...  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) (the ... €500.0 million principal amount of its 1.414% senior unsecured notes ... senior unsecured notes due 2026. The closing ... subject to the satisfaction of customary closing conditions.  The notes ... The Company intends to use the net proceeds ...
Breaking Biology News(10 mins):